SUBSCRIBE
SUBSCRIBE
News   Policy

Spectrum Pharmaceuticals, Inc. Says FDA Extends Review Date of Cancer Drug

February 23, 2009 | 
1 min read
Feb 23 (Reuters) - Spectrum Pharmaceuticals said U.S. regulators have extended the review date of its experimental cancer drug, Zevalin, to July 2.
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Courtesy of Sarepta Therapeutics
Layoffs
Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic
July 17, 2025
 · 
1 min read
 · 
Heather McKenzie
IN PARTNERSHIP WITH IQVIA
AI Is Taking Over Drug Safety Monitoring–But There’s One Thing It Can’t Replace
July 17, 2025
 · 
1 min read
 · 
Lori Ellis
Podcast
FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease
July 16, 2025
 · 
1 min read
 · 
Heather McKenzie
Entrance to the U.S. Department of Health and Human Services in Washington, DC
Layoffs
HHS Begins Formally Laying Off Employees
July 15, 2025
 · 
2 min read
 · 
Tristan Manalac